Showing results (211-220 of 223) with videos related to
Sort By:
Pageof 23
Blood Advances|August 14, 2025
Camidanlumab Tesirine for Relapsed or Refractory Classic Hodgkin Lymphoma: A Phase 2 StudyAlex F Herrera, Stephen M Ansell, Pier Luigi Zinzani, et al.Leukemia|October 13, 2023
Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemiaJan-Niklas Eckardt, Sebastian Stasik, Christoph Röllig, et al.Journal of Hematology & Oncology|May 13, 2022
Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestationsJan-Niklas Eckardt, Friedrich Stölzel, Desiree Kunadt, et al.The Journal of Infectious Diseases|July 13, 2023
Upper and/or Lower Respiratory Tract Infection Caused by Human Metapneumovirus After Allogeneic Hematopoietic Stem Cell TransplantationJose Luis Piñana, Gloria Tridello, Aliénor Xhaard, et al.Leukemia|February 19, 2026
Development of a prognostic scoring system for chronic myeloid leukemia in blast phaseMichael Lauseker, Tomasz Sacha, Hana Klamova, et al.Haematologica|November 7, 2024
Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY AllianceMarta Anna Sobas, Amin T Turki, Angela Villaverde Ramiro, et al.Leukemia|July 11, 2025
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemiaJane F Apperley, Dragana Milojkovic, Nicholas C P Cross, et al.Allergy|February 29, 2020
Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classificationJakub Trizuljak, Wolfgang R Sperr, Lucie Nekvindová, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2024
Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance LeukemiaChristoph Röllig, Björn Steffen, Christoph Schliemann, et al.American Journal of Hematology|January 6, 2026
Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction TherapyStefan Markus Dendorfer, Katharina Schmidt-Brücken, Michael Kramer, et al.Pageof 23